Search research articles
Contact Us
Filters
Showing results (331-340 of 429) with videos related to
Page
of 43
Sort By:
American Journal of Hematology
|
May 3, 2024
Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma
Sam Yuen, Tycel J Phillips, Rajat Bannerji, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2006
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies
Francis Giles, Thomas Fischer, Jorge Cortes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2002
Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors
Gary K Schwartz, Eileen O'Reilly, David Ilson, et al.
Oncotarget
|
September 10, 2021
The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series
Kevin Drenner, Gargi D Basu, Laurie J Goodman, et al.
Investigational New Drugs
|
April 17, 2013
Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors
Sunil Sharma, Elisabeth G de Vries, Jeffrey R Infante, et al.
Investigational New Drugs
|
April 22, 2015
Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors
Jennifer R Diamond, Benjamin Wu, Neeraj Agarwal, et al.
Oncotarget
|
October 26, 2022
Addendum: The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series
Kevin Drenner, Gargi D Basu, Laurie J Goodman, et al.
Oncotarget
|
July 16, 2014
Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells
Kyungsoo Ha, Warren Fiskus, Dong Soon Choi, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
|
August 24, 2021
Efficacy and safety of pegylated interferon-α2b in moderate COVID-19: a phase 3, randomized, comparator-controlled, open-label study
Shashi Bhushan B L, Sunil Wanve, Parshottam Koradia, et al.
Chest
|
October 2, 2020
Disparities in Sleep Health and Potential Intervention Models: A Focused Review
Martha E Billings, Robyn T Cohen, Carol M Baldwin, et al.
Page
of 43
Search research articles
Search
Showing results (331-340 of 429) with videos related to
Sort By:
Page
of 43
American Journal of Hematology
|
May 3, 2024
Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma
Sam Yuen, Tycel J Phillips, Rajat Bannerji, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2006
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies
Francis Giles, Thomas Fischer, Jorge Cortes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2002
Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors
Gary K Schwartz, Eileen O'Reilly, David Ilson, et al.
Oncotarget
|
September 10, 2021
The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series
Kevin Drenner, Gargi D Basu, Laurie J Goodman, et al.
Investigational New Drugs
|
April 17, 2013
Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors
Sunil Sharma, Elisabeth G de Vries, Jeffrey R Infante, et al.
Investigational New Drugs
|
April 22, 2015
Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors
Jennifer R Diamond, Benjamin Wu, Neeraj Agarwal, et al.
Oncotarget
|
October 26, 2022
Addendum: The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series
Kevin Drenner, Gargi D Basu, Laurie J Goodman, et al.
Oncotarget
|
July 16, 2014
Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells
Kyungsoo Ha, Warren Fiskus, Dong Soon Choi, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
|
August 24, 2021
Efficacy and safety of pegylated interferon-α2b in moderate COVID-19: a phase 3, randomized, comparator-controlled, open-label study
Shashi Bhushan B L, Sunil Wanve, Parshottam Koradia, et al.
Chest
|
October 2, 2020
Disparities in Sleep Health and Potential Intervention Models: A Focused Review
Martha E Billings, Robyn T Cohen, Carol M Baldwin, et al.
Page
of 43